BlackRock Health Sciences Term Trust (NYSE:BMEZ) Major Shareholder Saba Capital Management, L.P. Purchases 129,372 Shares of Stock

BlackRock Health Sciences Term Trust (NYSE:BMEZ) major shareholder Saba Capital Management, L.P. bought 129,372 shares of BlackRock Health Sciences Term Trust stock in a transaction dated Tuesday, March 26th. The stock was acquired at an average cost of 16.32 per share, with a total value of 2,111,351.04. Following the completion of the acquisition, the insider now directly owns 20,475,713 shares of the company’s stock, valued at approximately 334,163,636.16. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

• On Thursday, February 29th, Saba Capital Management, L.P. purchased 46,958 shares of BlackRock Health Sciences Term Trust stock. The shares were purchased at an average cost of 16.30 per share, with a total value of 765,415.40.
• On Monday, February 26th, Saba Capital Management, L.P. purchased 113,930 shares of BlackRock Health Sciences Term Trust stock. The shares were purchased at an average cost of 16.34 per share, with a total value of 1,861,616.20.
• On Thursday, February 22nd, Saba Capital Management, L.P. purchased 154,932 shares of BlackRock Health Sciences Term Trust stock. The shares were purchased at an average cost of 16.13 per share, with a total value of 2,499,053.16.
• On Tuesday, February 20th, Saba Capital Management, L.P. bought 193,297 shares of BlackRock Health Sciences Term Trust stock. The shares were bought at an average price of 15.92 per share, for a total transaction of 3,077,288.24.
• On Thursday, February 15th, Saba Capital Management, L.P. purchased 41,462 shares of BlackRock Health Sciences Term Trust stock. The shares were bought at an average cost of 15.82 per share, with a total value of 655,928.84.
• On Monday, February 12th, Saba Capital Management, L.P. acquired 83,360 shares of BlackRock Health Sciences Term Trust stock. The stock was acquired at an average cost of 16.08 per share, with a total value of 1,340,428.80.
• On Friday, February 9th, Saba Capital Management, L.P. bought 122,094 shares of BlackRock Health Sciences Term Trust stock. The stock was purchased at an average price of 15.97 per share, for a total transaction of 1,949,841.18.
• On Wednesday, February 7th, Saba Capital Management, L.P. acquired 100,354 shares of BlackRock Health Sciences Term Trust stock. The shares were bought at an average price of 15.81 per share, for a total transaction of 1,586,596.74.
• On Monday, February 5th, Saba Capital Management, L.P. purchased 93,967 shares of BlackRock Health Sciences Term Trust stock. The stock was acquired at an average price of 15.56 per share, for a total transaction of 1,462,126.52.
• On Friday, February 2nd, Saba Capital Management, L.P. purchased 53,462 shares of BlackRock Health Sciences Term Trust stock. The stock was acquired at an average price of 15.60 per share, for a total transaction of 834,007.20.

BlackRock Health Sciences Term Trust Price Performance

Shares of BlackRock Health Sciences Term Trust stock opened at 16.29 on Thursday. BlackRock Health Sciences Term Trust has a fifty-two week low of 12.93 and a fifty-two week high of 16.95. The business has a 50-day moving average price of 15.94 and a 200 day moving average price of 14.79.

BlackRock Health Sciences Term Trust Dividend Announcement

The firm also recently disclosed a monthly dividend, which will be paid on Thursday, March 28th. Investors of record on Friday, March 15th will be issued a $0.09 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 6.63%. The ex-dividend date is Thursday, March 14th.

Institutional Investors Weigh In On BlackRock Health Sciences Term Trust

Institutional investors have recently added to or reduced their stakes in the company. Raymond James Financial Services Advisors Inc. raised its stake in BlackRock Health Sciences Term Trust by 15.8% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 69,130 shares of the company’s stock valued at $1,387,000 after purchasing an additional 9,413 shares during the period. Cambridge Investment Research Advisors Inc. lifted its stake in shares of BlackRock Health Sciences Term Trust by 37.5% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 23,480 shares of the company’s stock valued at $471,000 after buying an additional 6,407 shares during the period. First Trust Advisors LP lifted its stake in BlackRock Health Sciences Term Trust by 8.3% during the first quarter. First Trust Advisors LP now owns 86,674 shares of the company’s stock worth $1,739,000 after purchasing an additional 6,654 shares during the period. Quantedge Capital Pte Ltd lifted its stake in BlackRock Health Sciences Term Trust by 448.0% during the first quarter. Quantedge Capital Pte Ltd now owns 69,600 shares of the company’s stock worth $1,396,000 after purchasing an additional 56,900 shares during the period. Finally, City of London Investment Management Co. Ltd. lifted its stake in BlackRock Health Sciences Term Trust by 45.6% during the first quarter. City of London Investment Management Co. Ltd. now owns 218,424 shares of the company’s stock worth $4,376,000 after purchasing an additional 68,452 shares during the period.

BlackRock Health Sciences Term Trust Company Profile

BlackRock Health Sciences Trust II’s (BMEZ) (the ‘Trust’) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries.